3 Pharmaceutical Stocks to Sell Now

Advertisement

This week, the overall grades of three pharmaceutical stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

TherapeuticsMD, Inc. (TXMD) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. TherapeuticsMD operates as a women’s healthcare product company in the United States. In Portfolio Grader’s specific subcategories of Earnings Revisions and Equity, TXMD also gets F’s. As of Jan. 29, 2015, 10.7% of outstanding TherapeuticsMD, Inc. shares were held short. To get an in-depth look at TXMD, get Portfolio Grader’s complete analysis of TXMD stock.

Slipping from a C to a D rating, Alcobra Ltd. (ADHD) takes a hit this week. The stock gets F’s in Earnings Momentum, Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of ADHD stock.

Lipocine, Inc.’s (LPCN) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Lipocine is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. The stock gets F’s in Earnings Revisions, Equity and Cash Flow. To get an in-depth look at LPCN, get Portfolio Grader’s complete analysis of LPCN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/01/3-pharmaceutical-stocks-to-sell-now-txmd-adhd-lpcn/.

©2024 InvestorPlace Media, LLC